A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group study

David Scott Miller, John A. Blessing, Samuel S. Lentz, Steven E. Waggoner, Denise Mackey

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objective. To estimate the antitumor activity of topotecan in women with advanced, persistent, or recurrent endometrial carcinoma previously treated with chemotherapy, and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients were those who had failed one prior chemotherapy regimen. Topotecan 0.5 to 1.5 mg/m2 was administered iv daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Of 29 patients entered, 28 were evaluable for toxicity and 22 were evaluable for response. Patient characteristics included a median age of 65, with 41% having prior radiation and 14% having prior hormonal therapy. Nine patients (41%) had a performance status (PS) of 0, 11 (50%) had a PS of 1, and 2 (9%) had a PS of 2. Patients received from 2 to 11 (with a median of 4) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 17 (61%) patients, leukopenia in 11 (39%), and thrombocytopenia in 7 (25%). Two deaths were considered potentially related to treatment. There was one (4.5%) complete and one (4.5%) partial response; 12 (55%) patients maintained stable disease and eight (36%) experienced increasing tumor. Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent endometrial carcinoma previously treated with chemotherapy.

Original languageEnglish (US)
Pages (from-to)247-251
Number of pages5
JournalGynecologic Oncology
Volume87
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Topotecan
Endometrial Neoplasms
Drug Therapy
Leukopenia
Therapeutics
Neutropenia
Thrombocytopenia
Disease Progression
Appointments and Schedules
Radiation

Keywords

  • Camptothecin
  • Topoisomerase-1 inhibition
  • Topotecan

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma : A gynecologic oncology group study. / Miller, David Scott; Blessing, John A.; Lentz, Samuel S.; Waggoner, Steven E.; Mackey, Denise.

In: Gynecologic Oncology, Vol. 87, No. 3, 2002, p. 247-251.

Research output: Contribution to journalArticle

Miller, David Scott ; Blessing, John A. ; Lentz, Samuel S. ; Waggoner, Steven E. ; Mackey, Denise. / A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma : A gynecologic oncology group study. In: Gynecologic Oncology. 2002 ; Vol. 87, No. 3. pp. 247-251.
@article{ba81e50218924a8d833783b3c7772d84,
title = "A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group study",
abstract = "Objective. To estimate the antitumor activity of topotecan in women with advanced, persistent, or recurrent endometrial carcinoma previously treated with chemotherapy, and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients were those who had failed one prior chemotherapy regimen. Topotecan 0.5 to 1.5 mg/m2 was administered iv daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Of 29 patients entered, 28 were evaluable for toxicity and 22 were evaluable for response. Patient characteristics included a median age of 65, with 41{\%} having prior radiation and 14{\%} having prior hormonal therapy. Nine patients (41{\%}) had a performance status (PS) of 0, 11 (50{\%}) had a PS of 1, and 2 (9{\%}) had a PS of 2. Patients received from 2 to 11 (with a median of 4) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 17 (61{\%}) patients, leukopenia in 11 (39{\%}), and thrombocytopenia in 7 (25{\%}). Two deaths were considered potentially related to treatment. There was one (4.5{\%}) complete and one (4.5{\%}) partial response; 12 (55{\%}) patients maintained stable disease and eight (36{\%}) experienced increasing tumor. Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent endometrial carcinoma previously treated with chemotherapy.",
keywords = "Camptothecin, Topoisomerase-1 inhibition, Topotecan",
author = "Miller, {David Scott} and Blessing, {John A.} and Lentz, {Samuel S.} and Waggoner, {Steven E.} and Denise Mackey",
year = "2002",
doi = "10.1006/gyno.2002.6804",
language = "English (US)",
volume = "87",
pages = "247--251",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma

T2 - A gynecologic oncology group study

AU - Miller, David Scott

AU - Blessing, John A.

AU - Lentz, Samuel S.

AU - Waggoner, Steven E.

AU - Mackey, Denise

PY - 2002

Y1 - 2002

N2 - Objective. To estimate the antitumor activity of topotecan in women with advanced, persistent, or recurrent endometrial carcinoma previously treated with chemotherapy, and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients were those who had failed one prior chemotherapy regimen. Topotecan 0.5 to 1.5 mg/m2 was administered iv daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Of 29 patients entered, 28 were evaluable for toxicity and 22 were evaluable for response. Patient characteristics included a median age of 65, with 41% having prior radiation and 14% having prior hormonal therapy. Nine patients (41%) had a performance status (PS) of 0, 11 (50%) had a PS of 1, and 2 (9%) had a PS of 2. Patients received from 2 to 11 (with a median of 4) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 17 (61%) patients, leukopenia in 11 (39%), and thrombocytopenia in 7 (25%). Two deaths were considered potentially related to treatment. There was one (4.5%) complete and one (4.5%) partial response; 12 (55%) patients maintained stable disease and eight (36%) experienced increasing tumor. Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent endometrial carcinoma previously treated with chemotherapy.

AB - Objective. To estimate the antitumor activity of topotecan in women with advanced, persistent, or recurrent endometrial carcinoma previously treated with chemotherapy, and to determine the nature and degree of toxicity of topotecan in this cohort of patients. Materials and methods. Eligible patients were those who had failed one prior chemotherapy regimen. Topotecan 0.5 to 1.5 mg/m2 was administered iv daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy. Results. Of 29 patients entered, 28 were evaluable for toxicity and 22 were evaluable for response. Patient characteristics included a median age of 65, with 41% having prior radiation and 14% having prior hormonal therapy. Nine patients (41%) had a performance status (PS) of 0, 11 (50%) had a PS of 1, and 2 (9%) had a PS of 2. Patients received from 2 to 11 (with a median of 4) courses of treatment. The most frequently observed grade 4 toxicities were neutropenia seen in 17 (61%) patients, leukopenia in 11 (39%), and thrombocytopenia in 7 (25%). Two deaths were considered potentially related to treatment. There was one (4.5%) complete and one (4.5%) partial response; 12 (55%) patients maintained stable disease and eight (36%) experienced increasing tumor. Conclusion. Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent endometrial carcinoma previously treated with chemotherapy.

KW - Camptothecin

KW - Topoisomerase-1 inhibition

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0036926109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036926109&partnerID=8YFLogxK

U2 - 10.1006/gyno.2002.6804

DO - 10.1006/gyno.2002.6804

M3 - Article

C2 - 12468321

AN - SCOPUS:0036926109

VL - 87

SP - 247

EP - 251

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -